Back to Search
Start Over
Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies
- Source :
- Journal of Nanobiotechnology, Vol 17, Iss 1, Pp 1-11 (2019), Journal of Nanobiotechnology
- Publication Year :
- 2019
- Publisher :
- BMC, 2019.
-
Abstract
- Background A cationic liposome-PEG-PEI complex (LPPC) was employed as a carrier for achieving targeted delivery of drug to human epidermal growth factor receptor-2 (HER2/neu)-expressing breast cancer cells. LPPC can be easily loaded with an anti-tumor drug and non-covalently associated with an anti-tumor antibody such as Herceptin that is clinically used to rapidly form immunoparticles within 1 h. Results Drug-loaded LPPC have an average size about 250 nm and a zeta potential of about 40 mV. Herceptin was complexed onto surface of the LPPC to form the drug/LPPC/Herceptin complexes. The size of curcumin/LPPC/Herceptin complexes were 280 nm and the zeta potentials were about 23 mV. Targeting ability of this delivery system was demonstrated through specific binding on surface of cells and IVIS images in vivo, which showed specific binding in HER2-positive SKBR3 cells as compared to HER2-negative Hs578T cells. Only the drug/LPPC/Herceptin complexes displayed dramatically increased the cytotoxic activity in cancer cells. Both in vitro and in vivo results indicated that Herceptin adsorbed on LPPC directed the immunocomplex towards HER2/neu-positive cells but not HER2/neu-negative cells. The complexes with either component (curcumin or doxorubicin) used in the LPPC-delivery system provided a better therapeutic efficacy compared to the drug treatment alone and other treatment groups, including clinical dosages of Herceptin and LipoDox, in a xenografted model. Conclusions LPPC displays important clinical implications by easily introducing a specific targeting characteristic to drugs utilized for breast cancer therapy. Electronic supplementary material The online version of this article (10.1186/s12951-019-0457-3) contains supplementary material, which is available to authorized users.
- Subjects :
- Receptor, ErbB-2
Pharmaceutical Science
Medicine (miscellaneous)
02 engineering and technology
01 natural sciences
Applied Microbiology and Biotechnology
Polyethylene Glycols
Polyethyleneimine
Cytotoxic T cell
skin and connective tissue diseases
media_common
Mice, Inbred BALB C
Chemistry
Lipo-PEG-PEI complex
021001 nanoscience & nanotechnology
lcsh:R855-855.5
SKBR3
Drug delivery
MCF-7 Cells
Heterografts
Molecular Medicine
Female
0210 nano-technology
medicine.drug
Drug
Curcumin
lcsh:Medical technology
Cell Survival
Surface Properties
media_common.quotation_subject
lcsh:Biotechnology
Biomedical Engineering
Antineoplastic Agents
Breast Neoplasms
Bioengineering
010402 general chemistry
In vivo
Herceptin
lcsh:TP248.13-248.65
medicine
Animals
Humans
Doxorubicin
Particle Size
Cell Proliferation
Research
Trastuzumab
In vitro
0104 chemical sciences
Drug Liberation
Liposomes
Cancer cell
Cancer research
Subjects
Details
- Language :
- English
- ISSN :
- 14773155
- Volume :
- 17
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Journal of Nanobiotechnology
- Accession number :
- edsair.doi.dedup.....5f7b9e1b921b74c5eb83157264d75f1a